FDA to review Mylan and Biocon’s biosimilar application
17 February 2017 | By Niamh Marriott, Digital Editor
The US Food and Drug Administration (FDA) has accepted Mylan and Biocon's biologics license application for MYL-1401H, a proposed biosimilar to Neulasta...